Elucidating the impact of FIC-1/FICD-mediated AMPylation on polyglutamine aggregation dynamics and toxicity
阐明 FIC-1/FICD 介导的 AMPylation 对聚谷氨酰胺聚集动力学和毒性的影响
基本信息
- 批准号:10464265
- 负责人:
- 金额:$ 3.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Adenosine MonophosphateAffectAgingAllelesAnimalsAttenuatedBiochemicalBiological AssayBuffersCRISPR interferenceCaenorhabditis elegansCellsCellular StructuresChemicalsDataDevelopmentDiseaseDisease modelExcisionFailureFamilyGeneral PopulationGenesGeneticGoalsHeat-Shock Proteins 70HumanHuntington DiseaseHuntington geneIn VitroInclusion BodiesIndividualInheritedKnock-outKnowledgeLengthLinkMJD1 proteinMachado-Joseph DiseaseMaintenanceMediatingMediator of activation proteinMolecularMolecular ChaperonesMutagenesisNeurodegenerative DisordersNeuronsOrthologous GenePathogenicityPathologicPathway interactionsPatientsPhysiologicalPost-Translational Protein ProcessingPost-Translational RegulationPrevalenceProcessProteinsQuality ControlRNA InterferenceRegulationReportingResearchRoleSignal PathwaySolubilityStressSumTechniquesTestingTherapeuticTherapeutic InterventionTissuesToxic effectTrinucleotide Repeat ExpansionType 1 Spinocerebellar AtaxiaWorkarmbasebiological adaptation to stressdisease-causing mutationfollow-upfunctional declinehuman embryonic stem cellin vitro Modelknock-downmisfolded proteinmutantneuron lossnoveloverexpressionpolyglutamineprotein aggregationprotein functionprotein misfoldingproteostasisresponsestem cellstargeted treatment
项目摘要
PROJECT SUMMARY
Huntington’s disease (HD) and spinocerebellar ataxia type 3 (SCA3) are inherited aging-associated diseases
that have a devastating impact on patients and family caretakers relative to their prevalence in the general
population. These conditions belong to a family of polyglutamine (polyQ) expansion diseases caused by
mutations resulting in the pathological expansion of trinucleotide (CAGn) repeats in distinct genes. Increases in
CAG repeat length give rise to proteins containing aberrantly expanded polyQ tracts, which interfere with normal
protein function and promote misfolding. Toxicity in these diseases is thought to arise in part from the formation
of pathological inclusion bodies comprised of aberrantly conformed mutant proteins, a hallmark observed in
numerous aging-associated neurodegenerative diseases. Despite extensive efforts to decipher the mechanisms
underlying toxicity in polyQ diseases, however, little progress has been made towards identifying targets for
therapeutic intervention.
Recently, the post-translational modification (PTM), AMPylation, has emerged as a novel regulator of HSP70
family chaperones, crucial components of the cell’s protein quality control machinery that buffer against protein
misfolding stress. Protein AMPylation is carried out by the fic-type AMPylase, FICD in humans, and its ortholog
FIC-1, in C. elegans, respectively. Work in our lab has established that FIC-1-mediated AMPylation directly alters
polyQ aggregation dynamics and toxicity. Further, my preliminary data as presented in this proposal identifies
fic-1 deficiency as sufficient to rescue survival of C. elegans expressing aggregation-prone polyQs during
development in a polyQ length-dependent manner. Taken together, these findings suggest that the loss of FIC-
1/FICD-mediated AMPylation bolsters proteostasis network capacity to alleviate toxicity induced by polyQ protein
aggregation.
This project will utilize cross-disciplinary approaches to generate a holistic characterization of FICD/FIC-1-
mediated AMPylation in polyQ diseases. To this end, I will harness the powerful genetics of C. elegans to uncover
novel pathway(s) that promote survival in the face of pathogenic polyQ aggregation (Aim 1). In tandem, I will
employ functional assays in neurons derived from HD and SCA3 patient stem cells to profile how FICD activity
affects polyQ aggregation and toxicity in these disease models (Aim 2). The results of these studies will advance
our knowledge of how AMPylation regulates proteostasis in polyQ diseases. The ultimate goal of my research is
to capitalize on these findings to develop translatable therapeutic approaches for aging-associated diseases.
项目概要
亨廷顿病 (HD) 和脊髓小脑性共济失调 3 型 (SCA3) 是遗传性衰老相关疾病
相对于一般情况而言,这对患者和家庭护理人员具有毁灭性影响
人口。这些病症属于由以下原因引起的聚谷氨酰胺 (polyQ) 扩张疾病家族:
突变导致不同基因中三核苷酸(CAGn)重复的病理性扩展。增加于
CAG 重复长度会产生含有异常扩增的 PolyQ 束的蛋白质,从而干扰正常的
蛋白质功能并促进错误折叠。这些疾病的毒性被认为部分是由形成的
由异常构象的突变蛋白组成的病理包涵体,这是在
许多与衰老相关的神经退行性疾病。尽管为破译机制付出了巨大的努力
然而,在确定 PolyQ 疾病的潜在毒性目标方面进展甚微。
治疗干预。
最近,翻译后修饰 (PTM) AMPylation 已成为 HSP70 的新型调节剂
家族伴侣,细胞蛋白质质量控制机制的重要组成部分,可缓冲蛋白质
错误折叠压力。蛋白质 AMP 化由人类的 fic 型 AMP 化酶、FICD 及其直系同源物进行
FIC-1,分别在秀丽隐杆线虫中。我们实验室的工作已证实 FIC-1 介导的 AMPylation 直接改变
PolyQ 聚集动力学和毒性。此外,我在本提案中提供的初步数据表明
fic-1缺陷足以挽救表达易聚集的polyQs的秀丽隐杆线虫的存活
以polyQ长度依赖的方式发展。总而言之,这些发现表明 FIC 的损失
1/FICD 介导的 AMPylation 增强了蛋白质稳态网络能力,以减轻 PolyQ 蛋白诱导的毒性
聚合。
该项目将利用跨学科方法来生成 FICD/FIC-1- 的整体特征
PolyQ 疾病中介导的 AMPylation。为此,我将利用秀丽隐杆线虫强大的遗传学来揭示
在面对致病性 PolyQ 聚集时促进生存的新途径(目标 1)。同时,我将
对 HD 和 SCA3 患者干细胞衍生的神经元进行功能测定,以分析 FICD 活性如何
影响这些疾病模型中的 polyQ 聚集和毒性(目标 2)。这些研究结果将推进
我们对 AMPylation 如何调节 PolyQ 疾病中蛋白质稳态的了解。我研究的最终目标是
利用这些发现来开发针对衰老相关疾病的可转化治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kate Matthys Van Pelt其他文献
Kate Matthys Van Pelt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kate Matthys Van Pelt', 18)}}的其他基金
Elucidating the impact of FIC-1/FICD-mediated AMPylation on polyglutamine aggregation dynamics and toxicity
阐明 FIC-1/FICD 介导的 AMPylation 对聚谷氨酰胺聚集动力学和毒性的影响
- 批准号:
10656221 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 3.95万 - 项目类别:
Parkinson's disease and aging affect neural activation during continuous gait alterations to the split-belt treadmill: An [18F] FDG PET Study.
帕金森病和衰老会影响分体带跑步机连续步态改变期间的神经激活:[18F] FDG PET 研究。
- 批准号:
400097 - 财政年份:2019
- 资助金额:
$ 3.95万 - 项目类别:
The elucidation of the mechanism by which intestinal epithelial cells affect impaired glucose tolerance during aging
阐明衰老过程中肠上皮细胞影响糖耐量受损的机制
- 批准号:
19K09017 - 财政年份:2019
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Does aging of osteocytes adversely affect bone metabolism?
骨细胞老化会对骨代谢产生不利影响吗?
- 批准号:
18K09531 - 财政年份:2018
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Links between affect, executive function, and prefrontal structure in aging: A longitudinal analysis
衰老过程中情感、执行功能和前额叶结构之间的联系:纵向分析
- 批准号:
9766994 - 财政年份:2018
- 资助金额:
$ 3.95万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 3.95万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 3.95万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 3.95万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9925164 - 财政年份:2016
- 资助金额:
$ 3.95万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9345997 - 财政年份:2016
- 资助金额:
$ 3.95万 - 项目类别:














{{item.name}}会员




